TJ Biopharma
PrivateLast Round
Series C
Extension
Sep 30, 2025
Total Funding Raised
$116M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
TJ Biopharma operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series C Extension round in February 2024.
TJ Biopharma is a biotechnology company that develops, manufactures, and commercializes innovative biologics for autoimmune diseases, immuno-oncology, and metabolic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Clean Manufacturing
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TJ Biopharma Comparables
Compare TJ Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genexine Inc | 77% | |
| Alphamab Oncology | 77% | |
| Biogen | 74% |
For institutional investors. Book with your work email.
TJ Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Sep 30, 2025 | ||||
| Series C Extension | Feb 7, 2024 | ||||
| Series B | Jul 16, 2022 | ||||
| Series A | Sep 15, 2020 |
For institutional investors. Book with your work email.
TJ Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oriental Fortune Capital | Series C Extension |
| CCIC Capital | Series C Extension |
| Hangzhou Industrial & Commercial Trust | Series A, Series B |
| Viva Biotech | Series A, Series B |
| Value Partners Group | Series A, Series B |
| Yijing Capital | Series C Extension |
| Zhejiang Haibang Private Equity Fund Management Co., Ltd. | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 694% MoM, reaching 1.2K.
- May 17, 2026
Grew 38% QoQ, from 8 to 11 employees.
For institutional investors. Book with your work email.
TJ Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TJ Biopharma's valuation, stock price, and market status.
Is TJ Biopharma a public or private company?
TJ Biopharma is a private company.
What is the current stock price of TJ Biopharma?
TJ Biopharma is a private company, so its shares have no public market price. Caplight tracks TJ Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TJ Biopharma worth (valuation)?
Valuation information for TJ Biopharma is not publicly available.
Can I buy TJ Biopharma stock?
TJ Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TJ Biopharma's last funding round?
TJ Biopharma's most recent funding round was Series C Extension on September 30, 2025.
Who are the main investors in TJ Biopharma?
Key investors in TJ Biopharma include CCIC Capital.
Will TJ Biopharma IPO soon?
No public IPO plans have been announced for TJ Biopharma.
How can I track TJ Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in TJ Biopharma's shares on secondary markets.